Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003195 · ClinicalTrials.gov registry record · Phase 2
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003195: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00003195 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003195, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of total-body irradiation, busulfan, and interferon alfa followed by peripheral stem cell or bone marrow transplantation in treating patients with multiple myeloma.
Interventions
- RADIATION radiation therapy
- PROCEDURE peripheral blood stem cell transplantation
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-12 |
| Est. Completion | 2000-11 |
| Phase | Phase 2 |
What the finished NCT00003195 record still lists
NCT00003195 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which radiation therapy is the first listed.
NCT00003195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003195 about?
NCT00003195 is a clinical study titled "Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectivenes...
What is the current status of trial NCT00003195?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-12. Estimated completion is 2000-11.
What interventions are being tested in trial NCT00003195?
The interventions under investigation include: radiation therapy (RADIATION), peripheral blood stem cell transplantation (PROCEDURE), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003195?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia